| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT04216797 Details | 2023-04-19 Interventional | 4 | 0 | Diazepam Anus Diseases Crigler-Najjar … Pain Syndrome Levator Ani Syn… | Enrollment was initially suspended due to COVID pandemic. As the number of cases subsided,
enrollment was reopened but never regained momentum. PI has left the site. - | |||
| NCT03790111 Details | 2023-04-19 Interventional | 2 | 53 | Cisplatin Gemcitabine Biliary Tract N… Biliary Tract C… | Did not meet pre-specified Progression-Free Survival at Month 6 for Stage 2 Analysis This study was halted prematurely as it did not meet pre-specified Progression-Free Survival at Month 6 for Stage 2 Analysis. Due to early discontinuation of the study with limited data, the study results (data) at Month 12 and End of Study may be unreliable and uninterpretable. | |||
| NCT01907009 NCT02349347 2012-000351-14 Details | 2023-04-19 Interventional | 2/3 | 29 | Lenograstim Melphalan Prostatic Neopl… Castrate Resist… | Early termination - | |||
| NCT01493453 Details | 2023-04-19 Interventional | 1 | 17 | Cyclophosphamid… Fludarabine Lymphoma, Non-H… CD19 Positive N… | Investigation into serious breach - | |||
| NCT05107427 Details | 2023-04-18 Interventional | 2 | 0 | Avelumab Carcinoma Carcinoma, Tran… Urothelial Carc… | Sponsor unable to proceed - | |||
| NCT02790710 Details | 2023-04-18 Interventional | 4 | 0 | Propranolol Compulsive Pers… Obsessive-Compu… Obsessive-compu… | Study has been withdrawn due to reconsideration of study design. - | |||
| NCT02054520 Details | 2023-04-18 Interventional | 2 | 47 | Ipilimumab Nivolumab Pembrolizumab Melanoma Metastatic Mela… Stage IV Melano… | Withdrawal of IND Early termination leading to small numbers of subjects analyzed. The enrollment and treatment phase of this trial was terminated early and the IND has been closed. | |||
| NCT00004935 Details | 2023-04-18 Interventional | 3 | 175 | Trastuzumab Breast Neoplasm… Breast Cancer | Trial is Life long follow-up: to reduce ressources and costs - trial terminated prematurely. - | |||
| NCT05496192 2022-000294-67 Details | 2023-04-14 Interventional | 2 | 0 | Nivolumab Carcinoma Carcinoma, Tran… Melanoma Urothelial Carc… | Replaced it with another clinical trial - | |||
| NCT04863248 2021-000186-32 Details | 2023-04-14 Interventional | 2 | 10 | Docetaxel Carcinoma, Non-… Lung Neoplasms Lung Cancer Metastatic Non-… NSCLC | Treatment paradigm in second- and third-line NSCLC is shifting away from docetaxel, the
backbone chemotherapy therapy used in this study. This study was terminated earlier than initially proposed by the Sponsor for non-safety related reasons; only 7 patients were randomized and treated. Therefore, only limited safety summary tables were generated, and no efficacy analyses were conducted. | |||
| NCT03618953 Details | 2023-04-14 Interventional | 1 | 8 | Atezolizumab HPV-Associated … | Virus potency titer of drug product as determined by an improved potency assay was lower than
originally determined by the assay described in the IND. - | |||
| NCT03179449 Details | 2023-04-14 Interventional | 1 | 0 | Ferrosoferric O… Brain Neoplasms Childhood Brain… | Accrual Factor - | |||
| NCT05191862 Details | 2023-04-13 Interventional | 1 | 19 | Cilostazol Intermittent Cl… | Randomization Error - | |||
| NCT05100160 Details | 2023-04-13 Interventional | 3 | 0 | Gabapentin Lung Diseases Pulmonary Disea… Thoracic | 0 patient accrual - | |||
| NCT04901988 Details | 2023-04-13 Interventional | 2/3 | 8 | Nivolumab Melanoma Melanoma (Skin) Melanoma, Stage… | Closed earlier than expected due to the need for a redesign to reflect the recent change in
standard of care guidelines. New design will include these treatments. - | |||
| NCT04823845 Details | 2023-04-13 Interventional | 1 | 0 | Adapalene Foot Diseases Warts Plantar Wart | Study never received IRB approval. - | |||
| NCT04540120 Details | 2023-04-13 Interventional | 2 | 49 | Dapansutrile COVID-19 Cytokine Releas… Syndrome Covid19 | Terminated due to the treatment environment for COVID-19 evolving with the pervasiveness of
vaccinations and other therapeutic modalities in mitigating against severe infection that has
eliminated a viable patient population for study enrollment. - | |||
| NCT02680626 Details | 2023-04-13 Interventional | 4 | 86 | Magnesium Sulfa… Ropivacaine Pain, Postopera… | Pfannenstiel hysterectomies are now rarely performed so cannot recruit eligible patients - | |||
| NCT02322814 2014-002230-32 Details | 2023-04-13 Interventional | 2 | 169 | Albumin-Bound P… Atezolizumab Paclitaxel Breast Neoplasm… Triple Negative… Breast Cancer | Sponsor's decision - | |||
| NCT04536532 Details | 2023-04-12 Interventional | 1/2 | - | Entecavir Hepatitis Hepatitis A Hepatitis B Hepatitis B, Ch… | New investigational drug on the same target already in clinical trials - |